Eisai Invests in Development of Personalized Cancer Rx via Stake in Biotech Startup | GenomeWeb

By Turna Ray

With a $200 million investment, Japanese drug developer Eisai last week launched a US-based personalized medicine subsidiary called H3 Biomedicine that will apply genetics and novel chemistry to develop tailored cancer treatments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.